HAIR LOSS AND REGENERATION PERFORMED ON ANIMAL MODELS

MEDA SANDRA ORASAN¹, IULIA IOANA ROMAN², ANDREI CONEAC³, ADRIANA MURESAN², REMUS IOAN ORASAN²

¹Department of Physiopathology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
²Department of Physiology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
³Department of Histology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

Abstract

Research in the field of reversal hair loss remains a challenging subject. As Minoxidil 2% or 5% and Finasteride are so far the only FDA approved topical treatments for inducing hair regrowth, research is necessary in order to improve therapeutical approach in alopecia. In vitro studies have focused on cultures of a cell type - dermal papilla or organ culture of isolated cell follicles. In vivo research on this topic was performed on mice, rats, hamsters, rabbits, sheep and monkeys, taking into consideration the advantages and disadvantages of each animal model and the depilation options. Further studies are required not only to compare the efficiency of different therapies but more importantly to establish their long term safety.

Keywords: hair regrowth, animal models, research in vivo, alopecia
three layers, starting from the outside: the cuticle (having several layers of flat, thin cells, overlapping one another), the cortex (containing the keratin bundles in rod-like cell structures) and the medulla (a disorganized and open area at the fiber’s center) [17,18].

On the other hand, in the dermis, we find the bulb, which maintains stem cells that not only re-grow the hair after it falls out, but are also recruited to repair skin after a wound [9].

The hair follicle pigmentary unit provides the hair shaft melanin components, due to precise interactions between follicular melanocytes, keratinocytes and specialized dermal papilla fibroblasts (also involved in wound healing) [19,20]. The dermal papilla has an important role in hair formation, growth and cycling [21]. The blood vessels from the dermal papillae nourish all hair follicles and offer nutrients and oxygen to epidermal cells in the lower layers.

In the human skin, the dermal papillae are small extensions of the dermis into the epidermis and at the surface of the hands and feet, they appear as epidermal or papillary ridges, also called fingerprints [22].

**Biology of the hair loss and hair regrowth**

Human hair is different from hair grown by mammals, due to the unsynchronized growth cycles. Even if there is a certain seasonal co-ordination, each human hair follicle works independently [23,24,25]. This mosaic human pattern consists of hair in different stages: 90% anagen (growth phase), 1-2% catagen (regression phase) and 8-9% telogen (resting phase). [26,27]. The cyclic changes from anagen to telogen via catagen involve rapid remodelling of both the epithelial and dermal components of hair follicles [28,29]. In animals, as in humans, the hair cycle is influenced by stimulatory and inhibitory factors, such as hormones, growth factors, cytokines, neuropeptides and pharmaceutical products [26,30,31].

The dermal papilla, as the main mesenchymal component, induces the new hair follicles formation and maintains hair growth [32]. In telogen phase the old hair is lost, but the follicle will be regenerated in early anagen, when a new hair grows up. In order for this to happen, the dermal papilla cells support an increased cell division and growth rate that also require a good supply of nutrients and a toxin-free environment for the growing cells. If these requirements are not fulfilled the follicles will remain in the telogen phase [33].

Two factors usually determine terminal hair miniaturization leading to hair loss. The first is the **shortening of the anagen**, within an abnormal hair cycle and the anagen: telogen rate shifting from 6:1 to 2:1. The consequence of this process would be a shortening of hairs, shaft loss and an increased number of hairs in telogen phase. The second factor with a negative impact on hair growth is the **small size dermal papilla or the hair matrix** leading to hair modification both in diameter and aspect. Final hair (thick and pigmented) turns into vellus (thin and white). Scientists have also discovered that in hair loss, the scalp suffers of vasoconstriction and hypoxia [34,35,36].

The sensitive response to androgen is the second feature characterizing human hair in contrast to the hair grown by mammals. An excess of androgens generates hair miniaturization and thinning, followed by hair fall and loss of pigment, mostly in the vertex and the crown-frontal area of the scalp [37,38].

There are some characteristics of the hair depending on localization in a specific site of the body: beard, axially and pubic hair react differently than hair from the scalp, as they are androgen-sensitive [12]. The metabolism of the testosterone into 5-alpha-dihydrotestosterone has also been of great research interest. Results show that good metabolism limits the length of hair growth (beard) and the 5 alpha-reductase deficiency produces strong thick hair (axilla and pubic area) [27,39,40,41,42].

On the other hand, androgens act on the hair via the dermal papilla and stimulate the production of terminal hairs after puberty, but have no hair growth effect on eyelashes and the occipital area [43,44]. Androgens seem to alter the production of regulatory factors (soluble paracrine factors and extracellular matrix components) by the dermal papilla cells [21].

**Consequences of hair loss**

Although a natural part of the aging process, hair loss represents a great concern for the patient, who suffers from anxiety and distress more severely than expected [45]. Several studies already showed that this common dermatological condition generates adverse psychosocial sequelae [46]. Cash et al found that the psychological effects of hair loss on women are far more severe than in male subjects. Surveys have shown that around 40% of women with alopecia have had marital problems and around 63% claimed to have career related problems [47].

Hair loss is a stressful experience for both sexes, but substantially more distressing for women, as they do not accept the disease, neither do they cope with it as easily as men [48]. Stress functions as a cause and risk factor in the development of the disease, but it is also a consequence of hair loss. Alopecia determines a poor quality of life by the physical, psychological and social consequences it produces. It causes low self-esteem, depression and distorts social perception and psychosocial functioning [49,50].

A large variety of over the counter products claim to treat hair loss pathology. This multibillion dollar, worldwide market of hair tonics, hair balms, hair masks, shampoos, leave in conditioners, topical solutions or foams function as potential anti-hair loss agents [51]. However, in most of the cases, clinical studies do not prove how these doubtful hair growth-promoters exert their expected effects of ceasing hair loss and enhancing hair regrowth [51].

As a consequence, clinically speaking, there is an increased number of patients with “great expectations”
who, encounter plenty of disappointments after the treatment [52,53].

**Evaluation of hair loss and hair regrowth**

Unfortunately, researchers do not have a standardized method to assess hair regrowth in vivo. Possible tools include scales of measuring hair regrowth based on percentage evaluations that can be performed with the naked eye (visualization and photographs of the area of interest) or by trichoscopy [49]. These qualitative assessments are limited in number, therefore, new, accurate and minimally invasive procedures are still needed.

To explore the efficiency of a topic substance in inducing hair growth, in vivo, researchers usually analyze the hair growing pattern in animal groups treated with different substances, compared to control by using the macroscopic aspect. The skin of the animals, usually the dorsal part, is observed and photographed either every 3 days or at specific time intervals (day 1, 7, 14 and 21 after depilation) in order to notice the start of hair regrowth period and the hair regrowth pattern. There are several hair regrowth potential scores, but one easy to use was described by Matsuda et al: 0 = no hair growth, 1 = less than 20% of hair growth, 2=20-39% of hair growth, 3=40-59% of hair regrowth, 4=60-79% of hair regrowth, 5=80-100% of hair regrowth [54]. Researchers also use self-designed scales of hair regrowth, such as: Type 4 (high hair density, full, thick fur), Type 3 (moderate hair density with no visible skin area), Type 2 (low hair density, with the visualization of the skin), Type 1 (uneven hair growth on the test area, skin easily seen) [55].

Trichoscopy is performed with a hand held device called dermatoscope, with polarized light to magnify and allow inspection of the skin. A decrease of hair diameter up to ten times or diameter variations can be detected by trichoscopy, so a correct hair regrowth evaluation can be performed.

As far as quantitative methods are concerned, an area of 1 cm² of skin with regrown hair is cut and weighed with an analytical balance for hair weight determination [56].

To further investigate the hair growth promoting effect of a certain substance, the histopathological examination offers a precise and necessary evaluation tool for hair regrowth. Usually, at the end of the treatment period, the rats are sacrificed and a skin biopsy is isolated in order to examine the histological features. The skin thickness and hair follicles localization in the dermis/subcutis can be evaluated by microscopic photograph (magnification x400). Taking into consideration the existent knowledge about hair cyclicity, the anagen induction is calculated with the formula: (number of follicles in subcutis)x100/ (number of follicles in dermis). Previous microscopical studies on animals showed an association of increasing skin thickness, follicle count and macroscopic development of skin pigmentation with anagen induction [26,31].

The hair growth cyclicity (anagen, catagen, and telogen phases) can be used as a diagnosis tool for the hair growth condition and also as a treatment assessment method for the hair growth promoting agent.

**Hair regrowth treatment**

The insufficient insight into the basic mechanism leading to alopecia together with therapies that failed to cure it, determined scientists to developed large research programs to overcome hair loss [57]. Despite the many treatment alternatives that have been tested, hair loss continues to remain a frequent dermatological condition.

Up to the present, pharmaceutical hair loss management includes only two FDA approved hair loss drugs: Finasteride and Minoxidil, both commonly used in clinical practice [46,51,58].

The hair growing effect of Minoxidil has been accidentally discovered, as this antihypertensive oral drug, caused side effects such as increasing hair growth on the scalp or even darkening the fine body hairs. The 2% topical formulation was approved by the FDA in the 1990s for use in treating androgenetic alopecia in men (for central/vertex hair loss only) and in females as well (in female pattern hair loss) [59]. The 5% formulation is allowed only for males and the foam version is associated with 70% self-reported improvement.

Minoxidil slows or stops hair loss and promotes hair growth because it is a vasodilator that increases the cutaneous blood flow to the scalp [60]. It is also a potassium channel opener, causing hyperpolarization of cell membranes, allowing more oxygen, blood and nutrients to reach the follicle [61]. Minoxidil contains an N-oxide group able to release NO, and besides being a vasodilator [62], it also acts as a nitric oxide agonist. However, it has no therapeutic action on the hormonal and genetic causes of hair loss.

Minoxidil usual dosage is 1 mg per day, applied topically, with slight massage on the affected area of the scalp and no contact with water allowed for at least 4 hours after application [63,64]. Minoxidil must be used as a continuous support for the hair follicles, otherwise the hair regrowth will cease and hair loss will begin again in 30 to 60 days if Minoxidil treatment is stopped for more than 6 months [65]. Several studies have shown that the efficacy of Minoxidil ranges from 20-40%, causing discontinuity of treatment in the majority of patients [66].

**Finasteride is considered a** dihydrotestosteron-suppressing 5 alfa-reductase inhibitor, recommended for male use only, in the treatment of androgenetic alopecia. It acts by decreasing the serum levels of dihydrotestosteron, stopping hair fall (in 48% of the cases) and stimulating hair regrowth (in 51% of the cases). Studies showed that 1 mg Finasterid oral treatment has a similar efficacy as daily topical Minoxidil application on the scalp, but their efficacy is seen after at least 4 months of daily usage [67,68]. These two treatments can be combined in order to boost the hair
follicles, but both treatments must be performed a-la-longue, if not, the hair regrowth effect will cease. Adverse reactions are rare, still sexual dysfunctions were reported in 4% of the cases [69,70].

Given the temporary efficacy of Finasteride and Minoxidil and the limited number of treatments available in alopecia, it is a challenge to discover new therapies in order to prevent hair loss and enhance hair regrowth [69,70]. Some substances diminish the physiopathological processes that induce hair loss, but clinical studies in this respect are lacking.

**Arginin** stimulates microcirculation, bringing in essential nutrients for hair bulb growth.

**Aminexil 1.5%** diminishes the rate of hair loss as it reduces the accelerated aging of the roots by fighting the process of fibrosis. It also maintains the elasticity of the tissue surrounding the hair root and prevents the stiffening of collagen sheets, in order to fasten the hair root within the scalp [52,53].

**SP94 peptide** is captured by the root and turned into the hair constructive elements for building up the fiber from root to tip.

**B5 and B6 Vitamins** function as cellular nutrients that nourish the hair roots and help generating beautiful, shiny hair, that becomes thicker and stronger from within [65].

**Thermal Spring Water** that contains anti-free radical Selenium, enhances the therapeutic action of **Madecassoside**, which inhibits the local micro-irritation, preventing the spreading to the capillary bulb [65].

Low Level Laser Therapy (LLLT) provides a promising treatment option for patients, this photobiomodulation produces a shifting of the follicles from telogen (resting phase) to anagen (active phase), preventing premature catagen development (hair falling phase) [71-73]. LLLT, through its low power coherent monochromatic red light, produces vasodilation and increases ATP production, also determining a modulation of Reactive Oxygen Species (ROS) and inflammatory mediators [74-76].

**Hair regrowth studies in vitro**

Human hair follicles are not proper research material due to ethical problems, invasive methods and limited amount of follicles that can be extracted for testing [77,78]. Cotsarelis et al., discovered that bald areas have the same number of stem cells as the normal scalp and also noticed that hair follicles decrease in size, but do not disappear. In alopecia, one of the major issues would represent the activation of stem cells converting to progenitor cells in the affected areas of the scalp [79].

Researchers insist in finding new natural and chemical agents, which may convert stem cells into progenitor cells and generate terminal hair [79,80].

In vivo models (experiments performed on natural animals and genetically manipulated models) as well in vitro research (cultures of a cell type - dermal papilla or organ culture of isolated cell follicles) have been used successfully, to obtain the data that we now possess about the function of the hair follicle in health or under disease [81-86].

Scientists may choose one of the two types of experimental studies taking into consideration the purpose of the research, the advantages and disadvantages it offers.

**Hair regrowth studies in vivo**

**Animal models**

For a better understanding of the physiopathological processes involved in hair loss and regeneration, animal models have been used in hair research since 1950 [87].

In vivo research on hair loss and regrowth was performed so far on mice, rats, hamsters, rabbits and sheep in laboratory conditions [88,89,90,91]. Lately, the interest in hair growth promoting agents has grown considerably and in the attempt to discover an ideal therapy for alopecia, new treatments have been studied even in stump-tailed macaque [92]. Still, researchers must take into consideration the differences between species regarding the follicular function and limited androgen-sensitive models [93]. The periodic intervals of rodent hair cycles, particularly the duration of the anagen phase are much more consistent and less susceptible to iatrogenic influences [94].

The normal hair cycling, including growth waves and hormonal control were studied on Wistar Bratislava rats and mice [95]. The black mouse C57BL/6 was used for the skin-free pigment and early visible pigmented tips of new anagen regrowth [91,96]. The C3H mouse model was the most widely reported for hair growth promotion, even thought the increased hair density of the animal and the wave pattern hair cycle progression presented disadvantages [95,96,97]. Laser therapy applied in C3H mouse, 20 second daily, 3 times per week, induced a much longer growth phase, after only 2 weeks of treatment, with most of the follicles from the tested area being in anagen hair growth phase [98].

The androgen action upon the hair follicles has been studied on spontaneous and genetically engineered nude mutant mice. Immunodeficient mice (with T and B cells deficiencies) were used as models for autoimmune disease mechanisms and androgenetic alopecia studies [96]. Also, by inhibiting the rejection of foreign skin, human skin grafts were applied and even rat dermal papillas continued to produce hair after reimplantation in vivo on a rat model [99,100,101].

Recently scientists discovered that a certain progenitor cell population in mice is analogous to the human cells. These mature cells were tested by injection on immunodeficient mice animal model and the results showed the development of new hair follicles and increased hair regrowth [98].

The Mesocricetus auratus (Golden hamster) was used for macroscopic assessment (hair density
dermatoscopy analysis) and microscopic evaluation (hair diameter analysis) as an animal model for hair regrowth [102].

Since Minoxidil 2% is thought to be the gold standard treatment for hair loss, scientists consider the validation of Minoxidil treatment on an animal model as being very important. Several studies have shown that topical Minoxidil affects the normal hair cycle by shortening telogen, causing premature entry of the resting follicles into anagen phase which will lead to an increased hair follicle size [103,104].

**Housing conditions**

Usually animals of either sex and weight were used in the studies. They were acclimatized to the experimental room at a temperature of 23 degrees Celsius, in controlled humidity conditions with a 12:12 h light and dark cycle for at least 7-14 days prior to the experiment. Usually, there was an individual housing or maximum 2 animals per cage (to avoid licking) with access to standard laboratory diet and water ad libitum. Following the experiment they were euthanized according to the current regulations. Some experiments were performed in triplicate for accurate results.

**Depilation conditions**

Experimental designs may ask for the whole back or body of the animal to be shaved, or there may be only some specific areas to be denuded for testing.

In Dr. Mester’s study, before each successive treatment, the skin was depilated by shaving, procedure that may induce mechanistic stimulation of hair growth, as previously reported in the literature. An experiment done on adult rats proved that after the fur was dyed and shaved, concluded that the regrowing hairs on the rat skin formed a system of linear loops, that were closely correlated with the shaving process [74,75].

In order to avoid this effect, some scientists do not shave the tested area of the animal model before each daily therapy. It has been also proved that physical factors influence the hair regrowth process: temperature triggers fast regrowth after shaving.

Depilation-induced hair cycle has a strict course: 9 days after depilation, the hair follicles enter the final stage of the growth cycle (anagen VI). Around day 17 the follicles enter the regression stage (catagen) and around day 20 after depilation, follicles get to the resting stage (telogen) [30].

Besides shaving, there are also other methods for depilation, such as a raisin mixture or a hair removal cream [91, 105].

**Conclusion**

As a conclusion, we tend to refine our knowledge on human hair diseases and hair regrowth by using proper animal models. Hair research provides further insights into the physiopathological pathways, genetic and cell biochemical mechanisms that could promise the cure of hair loss.

**Acknowledgments**

This paper was published under the frame of the European Social Found, Human Resources Development Operational Programme 2007-2013, project no. POSDRU/159/1.5/S/138776.

**References**

1. Helfert S, Waschburger P. The face of appearance-related social pressure: gender, age and body mass variations in peer and parental pressure during adolescence. Child Adolesc Psychiatry Ment Health. 2013 May 17;7:16.
2. Dohnt NK, Tiggemann M. Body image concerns in young girls: the role of peers and media prior to adolescences. J Youth Adolesc. 2006;35(2):141-151.
3. Chen J, Jackson T. Gender and age group differences in mass media and interpersonal influence on body dissatisfaction among Chinese adolescents. Sex Roles. 2012;66:3-20.
4. Andersson B. Development trends in reaction to social pressure from adults versus peers. Int J Behav Dev. 1979;2:269-286.
5. Jones DC, Vigfusdottir T, Lee Y. Body image and the appearance culture among adolescent girls and boys: An examination of friend conversations, peer criticism, appearance magazines and the internalization of appearance ideals. J Adolesc Res. 2004;19:323-339.
6. Randall VA. Hormonal regulation of hair follicles exhibits a biological paradox. Semin Cell Dev Biol. 2007;18:274-285.
7. Shorter K, Farjo NP, Pickles SM, Randall VA. Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. FASEB J. 2008;22(6):1725-1736.
8. Randall VA. Physiology and pathophysiology of androgenetic alopecia. In: De Groot LJ, Jameson JL (eds). Endocrinology. 4th edn. Philadelphia: WB Sanders; 2001: pp 2257-2268.
9. Krause K, Foitzik K. Biology of the hair follicles: the basics. Semin Cutan Med Surg. 2006;25:2-10.
10. Sabah NH. Controlled stimulation of hair follicle receptors. J Appl Physiol. 1974;36(2):256-257.
11. Ruben JA, Jones TD. Selective factors associated with the origin of fur and feathers. Amer Zool. 2000;40(4):585-596.
12. Randall VA, Sundberg JP, Philpott MP. Animal and in vitro models for the study of hair follicles. J Investig Dermatol Symp Proc. 2003;8:39-45.
13. Montagna W. The evolution of human skin. J Hum Evol. 1985;14:3-10.
14. Wheeler PE. The loss of functional body hair in man: the influence of thermal environment, body form and bipedality. J Hum Evol. 1985;14:23-28.
15. Jablonski NG, Chaplin G. Colloquium paper: human skin pigmentation as an adaptation to UV radiation. Proc Natl Acad Sci U S A. 2010;107(suppl2): 8962-8968.
16. Iyengar B. The hair follicle: a specialized UV receptor in the human skin? Bio Signals Recept. 1998;7(3):188-194.
17. Feughelman M. Mechanical properties and structure of alpha-keratin fibers: wool, human hair and related fibers. Sydney: UNSW Press; 1997.
18. Goodier M, Hordinsky M. Normal and aging hair biology and structure ‘aging and hair’. Curr Probl Dermatol. 2015;47:1-9.
19. Randall VA, Hibberts NA, Thornton MJ, Merrick AE, Hamada K, Kato S, et al. Do androgens influence hair growth by altering the paracrine factors secreted by dermal papilla cells? Eur J Pharm Sci. 2015;65:146-155.

20. Slominski A, Wortsman J, Plonka PM, Schallreuter KU, Paus R, Tobin DJ. Hair follicle pigmentation. J Invest Dermatol. 2005;124(1):13-21.
21. Lin CM, Li Y, Ji YC, Keng H, Cai XN, Zhang JK. Microencapsulated human hair dermal papilla cells: a substitute for dermal papilla? Arch Dermatol Res. 2008;300(9):531-535.
22. Liao YH, Kuo WC, Chou SY, Tsai CS, Lin GL, Tsai MR, et al. Quantitative analysis of intrinsic skin aging in dermal papillae by in vivo harmonic generation microscopy. Biomed Opt Express. 2014;5(9):3266-3279.
23. Randall VA, Ebling FJ. Seasonal changes in human hair growth. Br J Dermatol. 1991;124:146-151.
24. Orentreich N. Biology of the Skin. In: Montagna W, Dobson RL (eds). Sculp hair replacement in man. Pergamon Press, Oxford; 1969: 99–108.
25. Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: pathogenesis and potential for therapy. Expert Rev Mol Med. 2002;4(22):1-11.
26. Dry E. The coat of the mouse (Mus musculus). J Genet. 1926;16:287-340.
27. Randall VA: Androgens are the main regulator of human hair growth. In: Camacho F, Randall VA, Price V (eds). Hair and its Disorders: Biology, Pathology and Management. London: Martin Dunitz; 2000: 121–136.
28. Paus R. Therapeutic strategies for treating hair loss. Drug Discovery Today Ther Strateg. 2006;3(1):101-110.
29. Angelelli L, Cavina G, Moretti G, Siniscalchi P. Quantitative analysis of phospholipids of biochemical and pharmaceutical interest by means of thin layer chromatography: evaluation of the precision of the method. Farmaco Prat. 1966;21(9):493-507.
30. Muller-Rover S, Handjiski B, van der Veen C, Eichmüller S, Foitzik K, McKay IA, et al. A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages. J Invest Dermatol. 2001;117(1):3-15.
31. Datta K, Singh AT, Mukherjee A, Bhat B, Ramesh B, Burman AC. Eclipta alba extract with potential for hair growth promoting activity. J Ethnopharmacol. 2009;124 (3):450-456.
32. Reynolds AJ, Jahoda CA. Cultured dermal papilla cells induce follicle formation and hair growth by transdifferentiation of an adult epidermis. Development. 1992;115(2):587-593.
33. Courtois M, Loussouarn G, Hourseau C, Grollier JF. Ageing and hair growth in 5 alpha-reductase deficiency. Endocr Rev. 1993;14:577–593.
34. Courtois M, Loussouarn G, Hourseau C, Grollier JF. Hair follicle formation and hair growth by transdifferentiation of an adult epidermis. Development. 1992;115(2):587-593.
35. Reynolds AJ, Jahoda CA. Cultured dermal papilla cells induce follicle formation and hair growth by transdifferentiation of an adult epidermis. Development. 1992;115(2):587-593.
36. Whiting DA, Waldstreicher J, Sanchez M, Kaufman KD. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women. J Invest Dermatol Symp Proc. 1999;4:282-284.
37. Yip L, Rufaut N, Sinclair R. Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know. Australas J Dermatol. 2011;52(2):81-88.
38. GoodHeart HP. Photoguide to common skin disorders. Diagnostic and management. Lippincott Williams&Wilkins; 2009.
39. Wilson JD, Griffin JE, Russell DW. Steroid 5 alpha-reductase 2 deficiency. Endocur Rev. 1993;14:577–593.
40. Itami S, Kurata S, Sonoda T, Takayasu S. Characterization of 5 alpha-reductase in cultured human dermal papilla cells from beard and occipital scalp hair. J Invest Dermatol. 1991;96:57–60.
41. Thornton MJ, Laing I, Hamada K, Messenger AG, Randall VA. Differences in testosterone metabolism by beard and scalp hair follicle dermal papilla cells. Clin Endocrinol. 1993;39:633–639.
42. Hamada K, Thornton MJ, Laing I, Messenger AG, Randall VA. The metabolism of testosterone by dermal papilla cells cultured from human pubic and axillary hair follicles concurs with hair growth in 5 alpha-reductase deficiency. J Invest Dermatol. 1996;106:1017–1022.
43. Randall VA, Thornton MJ, Messenger AG. Cultured dermal papilla cells from androgen-dependent human hair follicles (e.g. beard) contain more androgen receptors than those from non-balding areas of scalp. J Endocrinol. 1992;133:141–147.
44. Hibberts NA, Howell AE, Randall VA. Balding hair follicle dermal papilla cells contain higher levels of androgen receptors than those from non-balding scalp. J Endocrinol. 1998;156:59–65.
45. Hadshiew IM, Foitzik K, Arck PC, Paus R. Burden of hair loss: stress and the underestimated psychosocial impact of telogen effluvium and androgenetic alopecia. J Invest Dermatol. 2004;123(3):455-457.
46. Cash TF, Price VH, Savin RC. Psychological effects of androgenetic alopecia on women: comparison with balding men and with female control subjects. J Am Acad Dermatol. 1993;29(4):568-575.
47. Hunt N, McHale S. Understanding alopecia. London: Sheldon; 2004.
48. Cash TF. The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol. 1992;26:926–931.
49. Alfonso M, Richter-Appelt H, Tosti A, Viera MS, Garcia M. The psychosocial impact of hair loss among men: a multinational European study. Curr Med Res Opin. 2005;21:1829-1837.
50. Hunt N, McHale S. The psychological impact of alopecia. BMJ. 2005;331:951-955.
51. Yoon JI, Al-Reza SM, Kang SC. Hair growth promoting effect of Zizyphus jujuba essential oil. Food Chem Toxicol. 2010;48(5):1350-1354.
52. Bandaranayake I, Mirmiran P. Hair loss remedies–separating fact from fiction. Cutis. 2004;73(2):107-114.
53. Chartier MB, Hoss DM, Grant-Kels JM. Approach to the adult female patient with diffuse nonscarring alopecia. J Am Acad Dermatol. 2002;47(6):809-818.
54. Nandeesh R, Kumar BS, Lakshman K, Khan S, Swamy VBN, Bharathi T, et al. Evaluation of hair growth activity of Buxus Wallichiana Baill extract in rats. Iran J Basic Med Sci. 2009;11(4):236-241.
55. Orasan MS, Coneac A, Mihu CM, Mare C, Muresan A. Minoxidil and Neoptide Topical Application Reinforced by Low-Level Laser Therapy on an Animal Model of Alopecia. Studia Chemia. 2015;60(2):295-308.
56. Orasan MS, Bofla P, Coneac A, Mitrea RD, Moldovan R, Mihu C, et al. Stimulation of hair regrowth using low level laser treatment in a rat model of alopecia. Dig J Nanomater Biostuctures. 2013;8(4):1571-1580.
57. Cash TF. The psychology of hair loss and its implications for patient care. Clin Dermatol. 2001;19(2):161-166.
58. Otoberg N, Finner AM, Shapiro J. Androgenetic alopecia. Endocrinol Metab Clin North Am. 2002;4(22):1-11.
1999;341(13):964-973.
60. Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, et al. A randomized, placebo-control trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50:541-553.
61. Schweiger ES, Boychenko O, Bernstein RM. Update on the pathogenesis, genetics and medical treatment of patterned hair loss. J Drugs Dermatol. 2010;9(11):1412-1419.
62. Stough D, Stenn K, Haber R, Parsley WM, Vogel JE, Whiting DA, et al. Psychological effect, pathophysiology, and management of androgenetic alopecia in men. Mayo Clin Proc. 2005;80(10):1316-1322.
63. Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil. J Am Acad Dermatol. 1987;16:688–695.
64. Tsuboi R, Tanaka T, Nishikawa T, Ueki R, Yamada H, Katsuoka K, et al. A randomized, placebo-controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. Eur J Dermatol. 2007;17:37-44.
65. Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol. 2008;59(4):547-566.
66. Tosti A, Duque-Estrada B. Treatment strategies for alopecia. Expert Opin Pharmacother. 2009;10:1017-1026.
67. Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010;146:1141-1150.
68. Braun-Falco O, Burgdorf WH, Plewig G, Wolff HH, LAndthaler M. Braun-Falco’s Dermatology. 3rd ed. Springer; 2009.
69. McPhee SJ, Papadakis MA. Current medical diagnosis and treatment. 46th ed. McGraw-Hill Medicale; 2007.
70. Kondo S, Hozumi Y, Aso K. Organ culture of human scalp hair follicles: effect of testosterone and oestrogen on hair growth. Arch Dermatol Res. 1990;282:442-445.
71. Desmet KD, Paz DA, Corry JJ, Eells JT, Wong-Riley MT, Henry MM, et al. Clinical and experimental applications of NIR-LED photobiomodulation. Photomed Laser Surg. 2006;24:121-128.
72. Hamblin MR, Demidova TN. Mechanisms of low level light therapy. Proc. SPIE. 2006;614001. doi:10.1117/12.646294.
73. Karu TI. Mitochondrial signaling in mammalian cells activated by red and near-IR radiation. Photochem Photobiol. 2008;84(5):1091-1099.
74. Mester E, Szende B, Gartner P. The effect of laser beams on the growth of hair in mice. Radiobiol Radiother (Berl). 1968;9:621-626.
75. Huang YY, Chen AC, Carroll JD, Hamblin MR. Biphasic dose response in low level light therapy. Dose Response. 2009;7(4):358-383.
76. Avram MR, Leonard RT Jr, Epstein ES, Williams JL, Bauman AJ. The current role of laser/light sources in the treatment of male and female pattern hair loss. J Cosmet Laser Ther. 2007;9(1):27-28.
77. Rudman SM, Philpott MP, Thomas GA, Kealey T. The role of IGF-1 in human skin and its appendages: morphogen as well as mitogen? J Invest Dermatol. 1997;109:770-777.
78. Soma T, Ogo M, Suzuki J, Takahashi T, Hibino T. Analysis of apoptotic cell death in human hair follicles . J Invest Dermatol. 1998;111(6):948–954.
Alopecia areata is a T-lymphocyte mediated autoimmune disease: lesional human T-lymphocytes transfer alopecia areata to human skin grafts on SCID mice. J Invest Dermatol Symp Proc. 1999;4:207–210.

98. Wikramanayake TC, Rodriguez R, Choudhary S, Mauro LM, Nouri K, Schachner LA, et al. Effects of the Lexington LaserComb on hair regrowth in the C3H/HeJ mouse model of alopecia areata. Lasers Med Sci. 2012;27(2):431-436.

99. Sundberg JP, King LE, Bascom C. Animal models for male pattern (androgenetic) alopecia. Eur J Dermatol. 2001;11:321–325.

100. Sundberg JP, Beamer WG, Uno H, Van Neste D, King LE. Androgenetic alopecia: in vivo models. Exp Mol Pathol. 1999;67:118–130.

101. Jahoda CA, Horne KA, Oliver RF. Induction of hair growth by implantation of cultured dermal papilla cells. Nature. 1984;311:560–562.

102. Gnann LA, Castro RF, Azzalis LA, Feder D, Perazzo FF, Pereira EC, et al. Hematological and hepatic effects of vascular epidermal growth factor (VEGF) used to stimulate hair growth in an animal model. BCM Dermatol. 2013 Oct 29;13:15. doi: 10.1186/1471-5945-13-15.

103. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150:186-194.

104. Zimber MP, Ziering C, Zeigler F, Hubka M, Mansbridge JN, Baumgartner M, et al. Hair regrowth following a Wnt- and follistatin containing treatment: safety and efficacy in a first-in-man phase I clinical trial. J Drugs Dermatol. 2011;10:1308-1312.

105. Matias JR, Malloy V, Orentreich N. Animal models of androgen-dependent disorders of the pilosebaceous apparatus. 1. The androchronogenetic alopecia (AGA) mouse as a model for male-pattern baldness. Arch Dermatol Res. 1989;281:247–253.